In a significant recent decision, the Central District of California (C.D. Cal.) held that injury claims related to Implanted Cardioverter Defibrillators (ICD) are preempted in the case of Tripolskiy v. Boston Sci. Corp., 2023 U.S. Dist. LEXIS 146689. For those of us who worked in the region among the palm trees and smog, the case has a particular resonance. But its impact is far broader, providing crucial guidance on premarket approval preemption and recalls.
Tripolskiy’s opinion is short, clear, and, most vitally, has determined premarket approval preemption in the context of a recalled device. Boston Scientific Corporation, a manufacturer of medical devices, became the subject following an injury claim related to their ICD device. The case carries significant implications for the medical device industry and could potentially influence future liability claims.
While the details of the decision are only available on subscription to legal news website JD Supra, the fact that the decision in favor of preemption was made despite the device being recalled is worth noting. It establishes a precedent that could determine the outcome of similar cases where recalled devices have caused injury.
Premarket approval preemption is a complex issue in law and it involves a delicate balance between ensuring consumers’ safety and encouraging medical innovation. The case reiterates the notion that FDA Premarket Approved (PMA) devices get an express preemption shield against most state law claims, granted by the Medical Device Amendments of 1976.
This decision, if upheld on appeal, could potentially offer manufacturers a stronger standpoint in asserting preemption defenses, even in cases involving recalled devices.
For detailed insights on the decision and its potential implications, you can access the court documents directly through
JD Supra’s coverage of the case.